An unpublished draft guidance the US Food and Drug Administration submits for White House review and clearance typically sparks little to no speculation by stakeholders on the extent and the details of the documents’ content.
Non-drug products containing hemp-derived cannabidiols aren’t typical products subject to the FDA’s regulatory oversight, though, and the document stating its...




